Author's response to reviews

Title: Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events. Results of a long-term follow-up study in routine clinical care

Authors:

Dietrich Rothenbacher (dietrich.rothenbacher@uni-ulm.de)
Michael M Hoffmann (michael.marcus.hoffmann@uniklinik-freiburg.de)
Lutz P Breitling (lutz.breitling@gmail.com)
Iris Rajman (iris.rajman@novartis.com)
wolfgang Koenig (Wolfgang-koenig@uniklinik-ulm.de)
Hermann Brenner (h.brenner@dkfz.de)

Version: 3 Date: 28 June 2013

Author's response to reviews: see over
Title: Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events. Results of a long-term follow-up study in routine clinical care

Point-to-point response
Version: 2 Date: 18 March 2013
Reviewer: Willibald Hochholzer
Reviewer's report: The authors have sufficiently addresses all raised items. Overall an interesting manuscript.

Response: Thank you very much for this positive evaluation.
Reviewer's report:

Major Compulsory Revisions

Point 1: The Authors addressed some of the issues raised by this reviewer in a superficial Manner [e.g. discussion of the association of the CYP2C19*2 polymorphism homozygous genotype itself with adverse outcome in patients not taking dual-platelet therapy; improvement in the introduction of the needed background (the Authors should at least mention and report the strong results of the collaborative meta-analysis of Mega and coworkers JAMA 2010 concerning the clinical setting of acute coronary syndrome undergoing percutaneous coronary intervention with stent implantation on clopidogrel therapy); in discussion, what is the new message and what adds their paper with respect to already published data; the Authors should improve the style of the writing]

Response: Thank you very much for the constructive comments to further improve the manuscript. We considered them and also tried to convey our message in clearer way. We now included some more information as requested and included also the report of Mega and coworkers published in JAMA 2010 as suggested (see page 3, para 2, lines 12-15, reference 6). In addition we made changes to convey the message and the added value of this work more clearly (see page 4, para 1, lines 11-12; page 12, para 1, lines 6-7). In addition, we proof-read the whole manuscript critically and made respective changes to improve the style of writing (see further marked changes in text).

Minor Essential Revisions

Point 2: Abstract: Change “CYP2C19*2 polymorphisms are” with “CYP2C19*2 polymorphism is”

Response: We changed as suggested (see page 2, para 1, line 1).

Point 2: Abstract: Add the full stop at the end of the sentence “In n=1050 patients with stable CHD at baseline genotyping of CYP2C19 allele *2 (rs4244285; 681G>A) was performed”

Response: We changed as suggested (see page 2, para 2, line 2).

Point 3: Introduction: Remove the full stop: “. Current evidence”

Response: We removed as suggested (see page 4, para 1, line 1).

Point 4: Methods: correct brackets “(rs4244285 (*2(681G>A)”

Response: We corrected the brackets (see page 6, para 2, line 2).

Point 4: Results: change “all auf Caucasian origin” with “all of Caucasian origin”

Response: We changed as suggested (see page 9, para 2, line 3).

Point 5: Tables should be improved.

There are several further errors.
Response: We proof-read all tables critically and made several changes to improve and especially label them in a consistent manner (see marked changes in tables one to five).